Noona Healthcare locks leading academic partnership to launch study on long-term tolerability of cancer immuno-oncology therapies
Palo Alto CA, USA: 30 July 2018 - Noona Healthcare, a leading Oncology Decision Support platform, announced today the initiation of a collaboration with Duke University School of Medicine to assess the long-term impact of immuno-oncology (IO) therapies on cancer patients who have experienced stable and durable remissions.
Duke has a distinguished track record in clinical research, led by the Duke Clinical Research Institute and academic faculty, to support the FDA in assessing the quality of real-world data.
More info on Noona's website.
Next > NGDATA accepted into G-Cloud 10 Framework
Previous > Sequana Medical announces the appointment of Kirsten Van Bockstaele as Chief Financial Officer